Fulfilling eligibility criteria for omalizumab as add-on treatment in severe asthma (equivalent to step 5 Global Initiative for Asthma treatment) (n=2068)
| Patients with at least 274 DDs ICSs (with or without LABAs) in the past 12 months (A) | 796 (38%) |
| Patients with at least 274 DDs LABAs (with or without ICSs) in the past 12 months (B) | 710 (34%) |
| Patients with A and B | 696 (34%) |
| Patients with at least two separate claims for systemic corticosteroids, at two different dates (C) | 1302 (63%) |
| Eligibility for add-on treatment with omalizumab in severe asthma: | |
| Patients with A, B and C | 497 (24%) |
DD: daily dose; ICS: inhaled corticosteroid; LABA: long-acting β2-agonist.